Novartis Agrees to Acquire Avidity Biosciences for $12 Billion

2025-11-25 | original

read original get Genomics platform → more articles

The Swiss pharmaceutical company says the purchase would complement its existing pipeline of treatments for neuromuscle disorders.

Explore topics: company says complement complement existing disorders existing